BMS-284756, a new des-fluoro(6) quinolone, was very active against 240 aerobic and 180 anaerobic isolates from bite victims. It inhibited 403 of 420 (96%) isolates, including those of Moraxella spp., CDC group EF-4, and Eikenella corrodens at <2 g/ml and those of all Pasteurella spp. and Bergeyella zoohelcum at <0.015 g/ml. Fusobacterium russii and 6 of 11 Fusobacterium nucleatum isolates of animal bite origin were resistant, but isolates of human bite origin were susceptible, which suggests that they were of a different subspecies.
Many of the 4.5 million Americans bitten by animals or humans each year require either therapeutic or prophylactic antimicrobial therapy; approximately 30,000 of these patients visit an emergency department for medical treatment, and an additional 10,000 are hospitalized with serious wound infections involving complex polymicrobial floras (4, 18) . While many patients receive a beta-lactam agent such as amoxicillinclavulanate, approximately 20% report a history of an adverse reaction to penicillin or other beta-lactam antibiotics (2) and require an appropriate alternative agent.
Older fluoroquinolones, such as ciprofloxacin, have limited activities against certain gram-positive aerobes and many anaerobic species typically encountered in human and animal bite wounds (5, 7) . BMS-284756 {T-3811ME; 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-5-isoindolyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid methanesulfonate monohydrate)} is a new des-fluoro (6) quinolone that lacks the six-position fluorine characterizing the previous generation of fluoroquinolones. Preliminary data indicate that this drug has a broad spectrum of activity against most gram-positive and gram-negative aerobes and anaerobes, including certain strains that are resistant to other fluoroquinolones (3, 8) .
Studies have focused on more typical isolates, especially respiratory and intra-abdominal pathogens (8, 17) , but have not evaluated the drug against the specific range of bacteria, such as Pasteurella species, Eikenella corrodens, Prevotella heparinolytica, and Porphyromonas macacae, commonly found in human and animal bite wound infections. In this study, we determined the activity of BMS-284756 against 420 aerobic and anaerobic strains recently isolated from such infections in humans. The specific sources of the strains were 117 dog bite, 156 cat bite, 132 human bite, and 15 other animal bite wounds. All isolates were identified by standard criteria (1, (9) (10) (11) (12) (13) 16) ; the numbers and species tested are given in Table 1 To ensure purity and good growth, frozen cultures were transferred twice on Trypticase soy blood or chocolate agar (Hardy Diagnostics, Santa Maria, Calif.) for the aerobes and on brucella agar supplemented with hemin, vitamin K 1 , and 5% sheep blood (Anaerobe Systems, Morgan Hill, Calif.) for the anaerobes. Susceptibility testing was performed according to NCCLS standards (14, 15) . Supplemented brucella agar was the basal medium used for the anaerobic species and for Eikenella corrodens and Bergeyella zoohelcum. Mueller-Hinton agar was used for staphylococci, and Mueller-Hinton agar supplemented with 5% sheep blood was used for the remainder of the organisms.
The agar plates were inoculated with a Steers replicator (Craft Machine Inc., Chester, Pa.). The inocula used were 10 4 CFU per spot for aerobic bacteria and 10 5 CFU for Eikenella corrodens and anaerobic bacteria. Control plates without antimicrobial agents were inoculated before and after the inoculation of each set of plates containing drugs. Plates with aerobic isolates were incubated at 35°C in an aerobic environment for 18 to 20 h and then examined; Eikenella corrodens, fastidious gram-negative bacilli, B. Zoohelcum, and streptococci were incubated in 5% CO 2 for 42 to 44 h. Plates with anaerobes were incubated in an anaerobic chamber (Anaerobe Systems) at 35°C for 44 to 48 h. The MIC was defined as the lowest concentration of an agent that yielded no growth or a marked change in growth compared to that on the control plate.
The full results of the study are presented in Table 1 . At Յ2 g/ml, BMS-284756 inhibited 96% (403 of 420) of the isolates studied and was the most active of the tested quinolones against enterococci, staphylococci, streptococci, and most of the anaerobic species. Overall, BMS-284756 and moxifloxacin had comparable activities, with BMS-284756 MICs generally being 1 dilution lower. All aerobic isolates except one (239 of 240; 99%), a strain of Corynebacterium jeikeium, were susceptible to BMS-284756 at Յ1 g/ml, while all Pasteurella species and Bergeyella zoohelcum were susceptible to BMS-284756 at Յ0.015 g/ml. BMS-284756 was also highly active against fastidious gram-negative organisms such as Haemophilus spp. and Capnocytophaga spp. It was slightly less active than the other quinolones against Neisseria spp. and Eikenella corrodens but still demonstrated a high level of effectiveness (MIC 90 [the MIC at which 90% of the organisms were inhibited], 0.06 g/ml) against both.
Hoellman et al. (8) studied the activity of BMS-284756 against 357 recently isolated anaerobes of human origin and found the MIC 50 and MIC 90 to be 0.5 and 2.0 g/ml, respectively. In our study, BMS-284756 was active against 164 of 180 (91%) anaerobic isolates at Յ2 g/ml (overall MIC 90 , 1g/ml), and it compared favorably with the other quinolones against Campylobacter spp. (MIC 90 , 1 g/ml) and Eubacterium spp.
(MIC 90 , 0.25 g/ml), as well as against Porphyromonas spp., Peptostreptococcus spp., Bacteroides tectus, and most strains of Prevotella spp. The overall MIC 90 s of the other quinolones were as follows: 2 g/ml for moxifloxacin, 4 g/ml for levofloxacin, and 8 g/ml for ciprofloxacin. BMS-284756, along with the other quinolones, including moxifloxacin, was less active against many strains of fusobacteria of animal bite origin. All nine strains of Fusobacterium russii and 6 of 11 animal bite strains of Fusobacterium nucleatum were resistant and required Ն4 g of BMS-284756 per ml for inhibition. Conversely, all 14 F. nucleatum strains of human bite origin were susceptible to BMS-284756 at Յ0.5 g/ml. While 3 of 12 F. nucleatum isolates from animal bites produced beta-lactamase, none of the 14 isolates from human bites produced beta-lactamase.
Prior studies (6, 7) have noted that some strains of F. nu- a Corynebacterium accolens (n ϭ 1), C. amycolatum (n ϭ 1), "C. aquaticum" (n ϭ 10), C. argentoratense (n ϭ 1), C. jeikeium (n ϭ 1), C. minutissimum (n ϭ 3), C. propinquum (n ϭ 1), and C. ulcerans (n ϭ 1).
b Centers for Disease Control and Prevention (CDC) groups EF-4a (n ϭ 4) and EF-4b (n ϭ 11). c Enterococcus avium (n ϭ 2), E. durans (n ϭ 5), E. faecalis (n ϭ 6), and E. malodoratus (n ϭ 1). d Actinobacillus actinomycetemcomitans (n ϭ 1) and Actinobacillus sp. (n ϭ 1); Capnocytophaga canimorsus (n ϭ 3), C. gingivalis (n ϭ 1), and Capnocytophaga spp. (n ϭ 2); Haemophilus aphrophilus (n ϭ 1), H. influenzae (n ϭ 1), and H. parainfluenzae (n ϭ 5); and Weeksella virosa (n ϭ 1).
e Moraxella atlantae (n ϭ 3), M. bovis (n ϭ 1), M. catarrhalis (n ϭ 10), M. lacunata (n ϭ 2), M. nonliquefaciens (n ϭ 3), and M. osloensis (n ϭ 2). f Neisseria cinerea-N. flavescens group (n ϭ 1), N. elongata subsp. elongata (n ϭ 2), N. elongata subsp. nitroreducens(n ϭ 2), N. subflava (n ϭ 4), N. weaveri (n ϭ 10), and an unidentifiable Neisseria sp. (n ϭ 1).
g Pasteurella canis (n ϭ 9) and P. dagmatis (n ϭ 6). h Staphylococcus hominis (n ϭ 2), S. hyicus (n ϭ 2), S. intermedius (n ϭ 6), S. saprophyticus (n ϭ 1), S. sciuri subsp. lentus(n ϭ 1), and S. warneri (n ϭ 7). i Streptococcus anginosus (n ϭ 7), S. constellatus (n ϭ 6), and S. intermedius (n ϭ 6). j Bacteroides ureolyticus (n ϭ 3), Campylobacter gracilis (n ϭ 5), C. mucosalis (n ϭ 2), and C. rectus (n ϭ 3). k Eubacterium aerofaciens (n ϭ 1), E. lentum (n ϭ 1), E. saburreum (n ϭ 3), E. yurii subsp. yurrii (n ϭ 2), and organisms with no good fit (n ϭ 6). l Fusobacterium nucleatum (n ϭ 10), F. nucleatum subsp. animalis (n ϭ 1), and F. necrophorum (n ϭ 1). m Fusobacterium necrophorum (n ϭ 3) and F. nucleatum (n ϭ 11). n Peptostreptococcus anaerobius (n ϭ 7), P. asaccharolyticus (n ϭ 1), P. ivorii (n ϭ 1), P. magnus (n ϭ 3), P. micros (n ϭ 8), P. prevotii (n ϭ 2), and P. tetradius (n ϭ 1). o Porphyromonas cangingivalis (n ϭ 4) and P. gingivalis (n ϭ 8).
p Prevotella denticola (n ϭ 2), P. intermedia-P. nigrescens group (n ϭ 7), P. melaninogenica (n ϭ 4), P. pallens (n ϭ 3), and P. tannerae (n ϭ 1). q Prevotella buccae (n ϭ 7), P. buccalis (n ϭ 1), P. disiens (n ϭ 1), P. oris (n ϭ 5), and an organism with no good fit (n ϭ 1). r Actinomyces israelii (n ϭ 1), A. meyeri (n ϭ 1), A. naeslundii (n ϭ 2), and A. viscosus (n ϭ 2); Lactobacillus catenaformis (n ϭ 1), L. lactis (n ϭ 1), L. plantarum (n ϭ 2), and a Lactobacillus species with no good fit (n ϭ 1). cleatum are resistant to ciprofloxacin, levofloxacin, moxifloxacin, and other quinolones but did not differentiate between animal and human sources. One could speculate that the resistance found in the present study might be associated with the use of fluoroquinolones for veterinary infections and in animal feed for growth enhancement. However, this explanation seems unlikely. A more likely cause of resistance appears to be that the animal strains of F. nucleatum are of one subspecies with an intrinsic resistance to quinolones, which they also share with other species, such as F. russii, and that the human strains are of a different subspecies. Further molecular studies are in progress to clarify this finding. BMS-284756 has an excellent broad spectrum of activity and consequently merits further evaluation as a therapeutic alternative in animal and human bite wound infections.
